Bionest team member Rachel Laing recently contributed to a feature in the January issue of PharmaVoice 
on the growing role and prominence of biomarker strategies in drug development and commercialization. In addition to helping to better identify those patients who will respond to a particular therapy, a biomarker strategy enables companies to differentiate their product and themselves in a highly competitive market. In cancer, and increasingly other indications, a well-validated biomarker for efficacy provides physicians, patients, and payers with a higher degree of certainty that the treatment will work in a specific patient population and helps to demonstrate value — an increasingly important attribute in this era of growing attention to drug pricing and therapeutic benefit.